Comparison of the effect of nebivolol and sotalol on the functional state of patients with paroxysmal supraventricular tachycardia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Paroxysmal supraventricular tachycardia (SVT) is subjectively poorly tolerated by patients and may be a predictor of a negative prognosis. The issue of optimizing its drug therapy remains relevant. Taking into account the multidirectional effects of antiarrhythmic drugs on the functional state of the body, a stepwise integrated approach to determine the effectiveness of treatment of patients with paroxysmal SVT is required. Objective. Determination of the effect of therapy with nebivolol or sotalol on the functional state of patients with paroxysmal SVT. Methods. The study involved 60 patients with paroxysmal SVT associated with stage II - III arterial hypertension (AH) and/or coronary artery disease (CAD), randomized into two groups for treatment with nebivolol (6.5±2.1 mg/day, n=30) or sotalol (164.3±46.8 mg/ day, n=30). As part of the combination therapy, lisinopril was prescribed (13.8±4.5 and 14.4±4.9 mg day), and if indicated, atorvastatin (12.9±4.3mg/day, n=14 and 14.2±4.6mg/day, n=15) andacetylsalicylicacid(95.8±14.4 mg/day, n=16and94.8±15.8mg/day, n=18), or rivaroxaban (Xarelto, Bayer, Germany) - 20 mg/day (n=2 and n=2, respectively). At baseline and 24 weeks after therapy, a quantitative assessment of the regulatory-adaptive status (RAS), echocardiography, treadmill test, 6-minute walk test, 24-hour Holter monitoring, and subjective assessment of the quality of life were performed. Results. Both schemes of combined pharmacotherapy significantly improved the structural and functional state of the heart, effectively suppressed SVT paroxysms, and improved the quality of life. At the same time, nebivolol had a positive effect on RAS and increased exercise tolerance to a greater extent. Conclusion. In patients with paroxysmal SVT associated with stage II-III arterial hypertension and/or coronary artery disease, the use of nebivolol compared to sotalol as part of a combination therapy may be preferable due to the positive effect on functional status.

Full Text

Restricted Access

About the authors

V. G Tregubov

Kuban State Medical University

I. Z Shubitidze

Regional Clinical Hospital № 2, Krasnodar

Email: iosif.shubitidze@mail.ru
Cardiologist, Cardiology Department

N. M Nazhalkina

Kuban State Medical University

References

  1. Almendral J., Castellanos E., Ortiz M. Update: Arrhythmias (V). Paroxysmal supraventricular tachycardias and preexcitation syndromes. Rev Esp Cardiol. (Engl Ed) 2012;65(5):456-69. doi: 10.1016/jrecesp.2011.11.026.
  2. Camm C.F., James C.A., Tichnell C., Murray B. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013;10(11):1661-68. Doi: 10.1016/j. hrthm.2013.08.032.
  3. Miyamoto K.J., Tsuchihashi K., Uno K., et al. Studies on the prevalence of complicated atrial arrhythmias, flutter, and fibrillation in patients with reciprocating supraventricular tachycardia before and after successful catheter ablation. Pacing Clin Electrophysiol. 2001;24(6):969-78. doi: 10.1046/j.1460-9592.2001.00969.x.
  4. Vanoli E.L., Dei Cas, Willenheimer R. Sudden death prevention in heart failure: The case of CIBIS HI. Heart int. 2006;2(2):73. doi: 10.4081/hi.2006.73.
  5. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl J. Med. 2001344(22):1651-58. doi: 10.1056/ NEJM200105313442201.
  6. Тарасов А.В. Вопросы безопасности анти-аритмической терапии. Consilium Medicum. 2014;16(10):44-9.
  7. Ломакин А.И., Шнайдер Н.А., Садыкова А.В., Стручков П.В.Актуальные вопросы функциональной диагностики. Медицина экстремальных ситуаций. 2011;4(38):111-18.
  8. Pokrovskii V.M., Polischuk L.V. Cardiorespiratory synchronism in estimation of regulatory and adaptive organism status. J. Int Neurosci. 2016;15(1):19-35. doi: 10.1142/S0219635216500060.
  9. Покровский В.М. Альтернативный взгляд на механизм формирования ритма сердца. Heart Lung Circul. 2003;12(1):18-24. doi: 10.1046/j.1444-2892.2003.00192.x.
  10. Канорский С.Г., Трегубов В.Г., Покровский В.М. Преимущества терапии квинаприлом у пациентов с артериальной гипертензией и хронической сердечной недостаточностью I-II функционального класса и сохраненной фракцией выброса левого желудочка. Кардиология. 2012;52(4):31-
  11. Трегубов В.Г., Кумачева Е.С., Спирина К.С. и др. Ивабрадин в комплексной терапии хронической сердечной недостаточности III функционального класса. Кубанский научный медицинский вестник. 2010;8:184-88.
  12. Трегубов В.Г., Покровский В.М., Канорский С.Г. Количественная оценка регуляторно-адаптивного статуса в определении тяжести хронической сердечной недостаточности. Клиническая медицина. 2012;90(8):32-5.
  13. Трегубов В.Г., Канорский С.Г., Покровский В.М. Регуляторно-адаптивный статус в оценке риска осложнений при хронической сердечной недостаточности. Кубанский научный медицинский вестник. 2012;3:172-79.
  14. Sule S.S., Frishman W. Nebivolol: new therapy update. Cardiol. 2006;14(5):259-64. doi: 10.1097/01. crd.0000223651.03023.8e.
  15. Шубик Ю.В., Чирейкин Л.В. Соталол в лечении аритмий. Вестник аритмологии. 1998;10:80-3.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies